APOA2 Antikörper (FITC)

Produktnummer ABIN7454056

Der Ziege Polyklonal anti-APOA2 Antikörper wird verwendet zum Nachweis von APOA2 in Proben von Human.

Kurzübersicht für APOA2 Antikörper (FITC) (ABIN7454056)

Target: APOA2 (Apolipoprotein A-II (APOA2))

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser APOA2 Antikörper ist konjugiert mit FITC

Applikation: Bitte anfragen

Klon: F04

Produktdetails anti-APOA2 Antikörper (FITC)

Verwendungszweck: Goat anti-Human Apo AII [F04] Antibody FITC Conjugated

Immunogen: Human Apolipoprotein AII

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02 % Sodium azide, pH 7.2

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Haltbarkeit: 12 months

Details zu APOA2

Target: APOA2 (Apolipoprotein A-II (APOA2))

Andere Bezeichnung: ApoAII

Hintergrund: Background: Apo AII comprises 25 % of HDL. It exists in human plasma as a dimer of 2 identical chains of 77 amino acid residues, joined by disulfide. The molecular weight is reported to be 8.7 kDa for a single chain (Brewer et al., 1972).Studies on mouse reported that apo AII may be proatherogenic (Warden et al., 1993), however, case-control study in the large European Prospective Investigation demonstrated that plasma Apo AII concentrations were strongly inversely correlated with CHD events. (Birjmohun et al., 2007)

Gen-ID: 336

NCBI Accession: NP_001634

UniProt: P02652

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Negative Regulation of Transporter Activity, Lipid Metabolism